| |
Newsroom /
Business
/
Business
/
Hypercholesterolemia Therapeutics – Pipeline Assessment and Market Forecasts to 2017
Hypercholesterolemia Therapeutics – Pipeline Assessment and Market Forecasts to 2017
Hypercholesterolemia Therapeutics Market is Forecast to Show Moderate Growth
Hyderabad,
AP,
India
(prbd.net)
28/04/2011
The hypercholesterolemia therapeutics market is predicted to witness marginal growth by 2017. This is primarily due to the probable launch of two novel therapies, MK-0524A and MK-0524B, from Merck & Co., Inc. The approval of Livalo (pitavastatin) in Europe will also positively impact the global hypercholesterolemia therapeutics market. However, many drugs are expected to lose their patent in the coming years like Lipitor (atorvastatin) and Lescol (fluvastatin) losing patent by 2011, followed by Niaspan
(Niacin) in 2013, Pravachol (pravastatin) in 2014 and Crestor (rosuvastatin) in 2016. GlobalData’s analysis suggests that the global hypercholesterolemia therapeutics market was worth $29 billion in 2010. The market is forecast to show a rise at a compound annual growth rate (CAGR) of 4%.
GlobalData’s pipeline analysis revealed that there are 22 candidates in various stages of clinical development for the hypercholesteromia therapeutics sector. The late stage of the pipeline, which consists of filed products and Phase III trials, has nine pipeline molecules, one of which, Pitavastatin, is filed for approval in Europe. There are six molecules in Phase II, Phase I consists of two molecules, and five molecules are in the pre-clinical and discovery phases. The pipeline consists of many novel therapies
such as MK-0524A and MK-0524B by Merck & Co., Inc., AEGR-733 by Aegerion Pharmaceuticals, Inc. and ISIS301012 by Genzyme Corporation, which are expected to be promising candidates for the hypercholesterolemia therapeutics market. The pipeline molecules differ from each other in terms of their mechanisms of action, and could capture significant portions of the current market on approval.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Hypercholesterolemia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
There are many therapies in the market to treat hypercholesterolemia by reducing blood low-density lipoprotein (LDL) and total cholesterol (TC) level. Statins, nicotinic acid and fenofibrates are mostly prescribed by medical practitioners to treat hypercholesterolemia.
The unmet need for the hypercholesterolemia therapeutics market was estimated to be approximately $4 billion. Currently, there are significant patient populations that are likely to switch over to new products with better efficacy and safety and the therapeutics pipeline contains many novel therapies with potentially better efficacy and safety profile which, if approved, will capture the market.
GlobalData, the industry analysis specialist, has released its new report, “Hypercholesterolemia Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global hypercholesterolemia market. The report identifies the key trends shaping and driving the global hypercholesterolemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hypercholesterolemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Hypercholesterolemia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|